Sun Pharmaceutical
One product, and it is the first genuinely new mechanism in topical acne treatment in decades — with a label candid enough to state that the mechanism, in acne, is unknown.
MODEL
New Drug Application, manufactured product, retail pharmacy dispensing on a prescriber's script.
The brand verdict
One product assessed, so this is a note rather than a pattern. Winlevi is clascoterone 1%, the first topical androgen receptor inhibitor approved for acne, and the only way to act on the androgen pathway in skin without a systemic anti-androgen. For adult women with jawline acne who cannot or will not take spironolactone, that is a real and recent addition.
The tolerability result is the strongest we have recorded against a vehicle arm. Across eight measured local reaction types, none was meaningfully worse on drug than on vehicle, and erythema and skin atrophy were both lower on drug. In a category where every alternative is a controlled burn, a treatment that irritates no more than its own base is a clinical asset in its own right.
The disclosure is unusually candid in three places. The label states that the mechanism of action for acne is unknown. It publishes HPA-axis suppression rates by age group — 5% of adults and 9% of adolescents at day 14 — with the four-week recovery interval. And it publishes the trial demographics, mean age 19.7 and 91% Caucasian, which quietly undercut the adult-female positioning the product is marketed on.
The economics are the problem, and they are stark. Around $509 discounted and $754 at retail for a 60 g tube, refrigerated before dispensing, with an instruction to discard one month after first opening. For most users that means throwing away a substantial fraction of an expensive tube on the label's own instruction. Copay assistance and coverage change the picture entirely, which is itself a reason the sticker price means nothing without checking.
- First-in-class topical androgen receptor inhibitor.
- Two identically designed vehicle-controlled trials with consistent results and published confidence intervals.
- Local reaction rates published against vehicle across eight reaction types.
- HPA-axis suppression rates published by age group, with the recovery interval.
- Potassium shifts published against vehicle.
- Systemic exposure quantified.
- States plainly that the mechanism of action for acne is unknown.
- Publishes trial demographics that undercut its own positioning.
- States storage and in-use limits explicitly, even though they make the product look worse.
The range
- R-392026-08-02
Winlevi
CLASCOTERONE CREAM 1%The first topical androgen receptor inhibitor — the drug adult women with hormonal acne have been waiting for, with irritation rates no worse than its own vehicle. Then read the storage line: discard one month after opening, on a tube that costs five hundred dollars.
CONDITIONAL$509 PER 60 G TUBE
What the reviewed offering tells us
This profile covers one offering. These findings describe its published terms and do not establish a pattern across the company's entire catalogue.
- 01
A new mechanism, honestly qualified
'The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown.' The receptor biology is established; the causal chain to lesion counts is inference, and the label says so on a product whose entire marketing rests on its mechanism.
- 02
Irritation no worse than vehicle
Erythema 12.2% on drug against 15.4% on vehicle. Scaling 10.5% against 10.4%. Skin atrophy 1.6% against 2.6%. The vehicle column is also a lesson: between 8% and 15% of people applying a plain cream to acne-prone skin twice daily for twelve weeks reported redness, flaking or itching.
- 03
Topical does not mean local
HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents after fourteen days, all recovering within four weeks of stopping, with potassium shifts in 5% against 4% on vehicle and a mean peak plasma concentration of 4.5 ng/mL. Small, reversible and measured — which is precisely what compounded topicals containing hormones or steroids cannot offer.
- 04
Trialled in teenagers, marketed to adults
Mean trial age 19.7, with 45% of subjects aged 12 to 17 and 91% Caucasian. The receptor is the same receptor and the extrapolation is reasonable, but the evidence for the adult hormonal-acne use this product is positioned around is extrapolation, and the demographic table says so more plainly than any marketing page.
- 05
A disclosure success punished by an economics failure
Discard one month after opening, or 180 days after dispensing, whichever is sooner — on a 60 g tube costing around $509. The information is right there on the label. It simply converts directly into money the patient throws away.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS
| PRODUCT | CONC. ON PAGE | CONC. FINDABLE | CONTRA-INDICATIONS | SIZE | SIDE EFFECTS |
|---|---|---|---|---|---|
| Winlevi | YES | YES | YES | YES | YES |
Reviewed offering
Winlevi
Worth buying for a specific person with a specific problem. Read who.